Market Intelligence, Clinical Progress, and High-Purity Reagents for KRAS-Driven Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KRAS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KRAS Mutant Recombinant Proteins (G12C, G12D, G12V, G13D, Q61H, WT) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View KRAS Products |
| Gene Delivery | KRAS Promise-ORF / Lentivirus Full-length ORF with hotspot mutations for stable cell line construction. HEK293 Expressed. |
View KRAS Products |
| Benchmark Standard | KRAS GTP-loaded Mutant Protein (Active State Reference) Recombinant positive control for biochemical assay calibration and nucleotide-exchange studies. |
View KRAS Products |
| Validator | KRAS siRNA Set For knockdown verification and specificity checks in cellular pathway assays. |
View KRAS Products |
| Related Target: NRAS | NRAS Recombinant Protein Paralog GTPase; critical for pan-RAS selectivity profiling and off-target liability assessment. |
View NRAS Products |
| Related Target: HRAS | HRAS Recombinant Protein Paralog GTPase; essential for counter-screening against pan-RAS inhibitor toxicity. |
View HRAS Products |
| Related Target: SOS1 | SOS1 Protein Upstream GEF; synthetic lethal screening partner. |
View SOS1 Products |
| Related Target: SHP2 | SHP2 (PTPN11) Protein Upstream phosphatase; combination therapy target. |
View SHP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity | Purified KRAS G12C, G12D, G12V, G13D, Q61H, and WT proteins (>95% purity, Endotoxin Controlled) for differential SPR/ITC and nucleotide-exchange assays. |
| Acquired Drug Resistance (e.g., Y96D, R68S, H95D) | Resistance mutant panel (Y96D, H95D, R68S) available as recombinant proteins; Sequence Verified for secondary screening. |
| Paralog Selectivity (KRAS vs NRAS/HRAS) | Ortholog panel (KRAS, NRAS, HRAS) strictly Sequence Verified by mass spec for pan-RAS selectivity assessment. |
| Lack of Cellular Controls | Lentivirus particles for stable mutant KRAS cell line construction; GDP/GTP-loaded protein states available. |
| False Positives / Specificity | Validated siRNA included for target knockdown verification in cellular assays (e.g., pERK, pMEK). |
Live KRAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KRAS therapeutics is intensifying, with major players shifting focus from first-generation covalent G12C inhibitors to pan-KRAS inhibitors and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic and encounter acquired resistance (e.g., Y96D mutations), the next wave of R&D is targeting G12D/G12V alleles, inactive vs. active state conformations, and rational combination therapies to establish durable oncology solutions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Small Molecule (G12C) | Amgen (Sotorasib), BMS/Mirati (Adagrasib) | NSCLC, Colorectal Cancer | Covalent binding kinetics & state selectivity (Need GDP/GTP-loaded G12C protein) |
| Non-covalent Small Molecule (Pan / G12D) | Revolution Medicines, Mirati, Novartis | Pancreatic, Colorectal, NSCLC | Pan-mutant / WT selectivity (Need full mutant panel + NRAS/HRAS counter-screen) |
| PROTAC / Degrader | Arvinas, Kymera, Preclinical biotechs | Refractory Cancers, Solid Tumors | Ternary complex formation (Need purified KRAS + E3 ligase components) |
| Combination (EGFR + KRAS) | Amgen, AstraZeneca, Novartis, Boehringer Ingelheim | Colorectal Cancer, Advanced Solid Tumors | Pathway redundancy blockade (Need KRAS & EGFR co-expression cell lines; related SOS1/SHP2/MEK targets) |
Molecular Differentiation & Assay Strategy
Affinity & Binding Mechanism
- Nucleotide State Selectivity: G12C covalent inhibitors (e.g., Sotorasib) prefer GDP-bound inactive state; next-generation pan-KRAS inhibitors (e.g., RMC-6236) target GTP-bound active state. Assays require strictly GDP-loaded vs GTP-loaded recombinant proteins for SPR/BLI kinetics.
- Covalent Binding Kinetics: For G12C drugs, assess adduct formation rate and residence time. TarMart's high-purity G12C protein (free Cys) is ideal for mass-spec adduct validation and ITC.
Selectivity & Safety
- Paralog Selectivity (KRAS vs NRAS vs HRAS): Pan-RAS inhibitors must avoid HRAS/NRAS inhibition to prevent toxicity. TarMart provides sequence-verified NRAS and HRAS full-length proteins for paralog selectivity panels.
- Mutant vs WT Selectivity: WT KRAS inhibition is toxic. TarMart's WT / G12C / G12D / G12V / G13D / Q61H protein panel enables quantitative selectivity window determination.
Resistance Management
- Resistance Mutation Coverage: Next-generation drugs must retain activity against Y96D (steric hindrance), H95D/Q (electronic effects), R68S (allosteric site). TarMart offers KRAS resistance mutant protein library (Y96D, H95D, R68S, Q99L) for secondary screening.
Recommended Assay Panel
| Screening Stage | Recommended Assay | TarMart Key Reagent |
|---|---|---|
| Early Biochemical | GDP/GTP nucleotide exchange inhibition; GTPase activity | GDP-loaded / GTP-loaded KRAS G12C/D/V proteins (>95% purity) |
| Binding Kinetics | SPR / BLI / ITC | Full-length KRAS mutant proteins; multiple nucleotide loading states |
| Selectivity Screening | Differential binding / FP / AlphaScreen | KRAS WT + Mutant Panel; NRAS / HRAS control proteins |
| Resistance Assessment | Mutant affinity ranking; covalent adduct mass spec | KRAS resistance mutant proteins (Y96D, H95D, R68S) |
| Cellular Functional | pERK / pMEK pathway inhibition; Ba/F3 proliferation | KRAS mutant Lentivirus (stable cell line construction); KRAS siRNA |
Cross-sell Targets
To build a complete RAS pathway solution, recommend the following synergistic targets to KRAS customers:
- NRAS: Paralog GTPase; essential for pan-RAS selectivity profiling. NRAS mutations are frequent in melanoma.
- HRAS: Paralog GTPase; core control for pan-RAS inhibitor toxicity assessment. HRAS mutations are relevant in bladder and head/neck cancers.
- EGFR: Upstream receptor tyrosine kinase. In colorectal cancer, KRAS mutation confers resistance to EGFR antibodies; KRASi + EGFRi combination therapy is clinically validated.
- SOS1: Major guanine nucleotide exchange factor (GEF) for KRAS; SOS1 inhibitors lock KRAS in druggable GDP-bound state.
- SHP2: Hub node connecting RTK to RAS pathway; SHP2 allosteric inhibitors block upstream feedback activation.
TarMart provides a complete protein and viral toolkit (KRAS + NRAS + HRAS + EGFR + SOS1 + SHP2) to enable customers to build an integrated platform from biochemical screening, selectivity validation, to cellular combination therapy evaluation.